1型糖尿病中屈光不正与视网膜病变结局:DCCT/EDIC研究
基于糖尿病控制与并发症试验(DCCT)及其后续流行病学干预与并发症研究(EDIC)30年随访,评估1型糖尿病患者屈光不正与糖尿病视网膜病变(DR)的关系。Cox模型显示远视与2步、3步DR进展及增殖性DR(PDR)风险升高独立相关,近视与DR进展风险无关。
要点
- 远视是2步和3步DR进展及PDR的独立危险因素。
- 近视与DR进展风险无关。
- 屈光状态或可辅助DR风险分层。
核心结论
- 近视与DR进展风险无关。
- 远视是2步和3步DR进展及PDR的独立危险因素。
研究设计与样本
- 临床试验,纳入DCCT/EDIC中1型糖尿病个体,30年间系列测量屈光误差与DR分期。
主要发现
- 未调整模型中,远视 compared with 正视,2步进展HR 1.29(95%CI 1.05-1.59),3步进展HR 1.35(95%CI 1.05-1.73),PDR HR 1.40(95%CI 1.02-1.92)。
- 调整DCCT治疗组、队列、年龄、性别、吸烟、糖尿病病程、收缩压和舒张压、脉搏、LDL、HDL、甘油三酯、白蛋白排泄率及DCCT/EDIC平均更新HbA1c后,远视与2步进展(HR 1.28;95%CI 1.03-1.58)、3步进展(HR 1.30;95%CI 1.00-1.68)及PDR(HR 1.38;95%CI 1.00-1.90)的关联仍显著。
- 未调整模型中,近视与全部5种DR结局均无关;调整模型中,近视仅与2步进展边缘相关(HR 1.11;95%CI 1.00-1.24)。
关键数值与推荐
- 近视定义:球镜等效≤-0.5;正视:>-0.5且<0.5;远视:≥0.5。
- DR结局包括2步或3步进展、PDR、临床显著黄斑水肿(CSME)、糖尿病黄斑水肿(DME)或眼部手术。
临床怎么用
- 对1型糖尿病患者,远视状态可提示DR进展和PDR风险较高,或需更密切眼底监测。
- 近视不应被视为DR进展的保护因素或低风险标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the relationship between refractive error and diabetic retinopathy (DR). DESIGN: Clinical trial. PARTICIPANTS: Type I diabetes individuals with serial refractive error and DR stage measurements over 30 years in the Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study. METHODS: Stage of DR was measured every 6 months from standard fundus photographs, and refractive error was measured annually during the 6.5 years of DCCT; then, both were staggered every fourth year during EDIC with the full cohort measured at EDIC years 4 and 10. Outcomes of DR were 2- or 3-step progression, presence of proliferative DR (PDR), clinically significant macular edema (CSME), diabetic macular edema (DME), or ocular surgery. Myopia, emmetropia, and hyperopia were defined as a spherical equivalent of ≤-0.5, >-0.5 and <0.5, and ≥0.5, respectively. MAIN OUTCOME MEASURES: For each outcome separately, Cox proportional hazard (PH) models assessed the association between the refractive error status and the subsequent risk of that outcome, both without and with adjustment for potential risk factors. RESULTS: Hyperopia was associated with a higher risk of 2-step progression (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.05-1.59), 3-step progression (HR, 1.35; 95% CI, 1.05-1.73), and PDR (HR, 1.40; 95% CI, 1.02-1.92) compared with emmetropia in unadjusted models. These associations remained significant after adjustment for DCCT treatment group, cohort, age, sex, smoking, duration of diabetes, systolic and diastolic blood pressures, pulse, low-density lipoprotein, high-density lipoprotein, triglycerides, albumin excretion rate, and DCCT/EDIC mean updated hemoglobin A1c (HbA1c) (2-step progression: HR, 1.28; 95% CI, 1.03-1.58; 3-step progression: HR, 1.30; 95% CI, 1.00-1.68; PDR: HR, 1.38; 95% CI, 1.00-1.90). Myopia was not associated with any of the 5 DR outcomes in the unadjusted models and only marginally associated with 2-step progression (HR, 1.11; 95% CI, 1.00-1.24) in the adjusted models. CONCLUSIONS: Myopia is not associated with DR progression risk. Hyperopia is an independent risk factor for 2-step and 3-step DR progression and PDR.
引用
- Hainsworth DP, Gao X, Bebu I, et al. Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Ophthalmology. 2020. PMID: 32941962. doi:10.1016/j.ophtha.2020.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。